1Annibali O, Marchesi F, Petrucci MT, et al. Relapse of IgA lambda multi- ple myeloma presenting as obstuctive jaundice and abdominal pain [ J ]. Onkolgie,2009,32 : 119 - 121.
3Barth C, Bosse A, Andus T. Severe acute cholestatic hepatitis by infiltra- tion of monocloual plasma cells in multiple myeloma [ J ]. Z Gastroen- terol, 2005,43 ( 10 ) : 1129 - 1132.
6Mino T, Sakai A, Kinoshita M, et al. Successful treatment with bortezomib for a patient with plasma cell leukemia accompanied by severe hyperbil- irubinemia[ J]. Rinsho Ketsueki ,2012,53 ( 1) :92 - 96.
7Hoy SM. Subcutaneous bortezomib in multiple myeloma [ J ]. Drugs, 2013,73( 1 ) :45 -54.
2[1]Terada T,Hirata K,Hisada Y,et al.Obstructive jaundice caused by the deposition of amyloid-like substances in the extrahepatic and large intrahepatic bile ducts in a patient with multiple myeloma[J].Histopathology,1994,24(5):485-487.
3[2]Mitchell DG,Hill MC.Obstructive jaundice due to multiple myeloma of the pancreatic head:CT evaluation[J].J Comput Assist Tomogr,1985,9(6):1118-1119.
4[3]Macias Robles MD,Navia-Osorio Garcia-Braga JM,Menendez Caro JL,et al.Jaundice secondary to intrahepatic deposit of light chains as a presenting form of multiple myeloma[J].An Med Interna,1994,11(2):74-76.
5[4]Miehopoulos S,Petraki K,Petraki C,et al.Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome[J].Dig Dis Sci,2002,47(4):730-734.
6van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica, 2007; 92(10):1399 -1406.
7Richardson PG, Xie W, Mitsiades C, et aL Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol, 2009; 27(21 ) :3518 - 3525.
8Berenson JR. Hematology:Bortezomib in newly diagnosed multiple myeloma. Nat Rev Clin Oncol, 2009 ; 6 (5) :255 - 256.
9Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia, 2009 ; 23 ( 3 ) :449 - 456.
10Basler M, Lauer C, Beck U. et al. The proteasome inhibitor bortezomin enhances the susceptibililty to viral infection. J Immunol, 2009 ,183 (10) :6145 -6150.
